Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 2, 2017, Pages 282-288

  Ho, Samuel B ^a   Monto, Alexander ^b,g   Peyton, Adam ^c,g   Kaplan, David E ^d   Byrne, Sean ^e   Moon, Scott ^e   Copans, Amanda ^e   Rossaro, Lorenzo ^e   Roy, Anupma ^e   Le, Hadley ^e   Dvory Sobol, Hadas ^e   Zhu, Yanni ^e   Brainard, Diana M ^e   Guyer, William ^e   Shaikh, Obaid ^d,g   Fuchs, Michael ^d,g   Morgan, Timothy R ^f,g   Brown, Geri ^g   Cheung, Ramsey ^g   Gilliam, Bruce ^g   Ho, Sam ^g   Jeffers, Lennox ^g   Kaplan, David ^g   Lim, Joseph ^g   Naggie, Susanna ^g   Pandya, Prashant ^g   Rimland, David ^g   Talwani, Rohit ^g   Yoffee, Boris ^g   Cartwright, Emily ^g   more..

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Miami Veterans Affairs Healthcare System   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e GILEAD SCIENCES   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^g Richmond Veterans Affairs Medical Center ^*

Author keywords

Clinical Trial; DAA; NS5B Inhibitor; Substance Abuse; VA

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALCOHOL ABUSE; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COMPENSATED LIVER CIRRHOSIS; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ESOPHAGUS VARICES BLEEDING; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERBILIRUBINEMIA; HYPERHIDROSIS; INSOMNIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; POSTTRAUMATIC STRESS DISORDER; PROSPECTIVE STUDY; RASH; RHABDOMYOLYSIS; SEPSIS; SUBSTANCE ABUSE; SUSTAINED VIROLOGIC RESPONSE; THORAX PAIN; TONGUE EDEMA; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VETERAN; VOMITING; ADVERSE EFFECTS; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VETERANS;

EID: 84990313627     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.05.024     Document Type: Article

References (20)

1. 1 Beste, L.A., Ioannou, G.N., Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev 37 (2015), 131–143.
2. 2 Backus, L.I., Belperio, P.S., Loomis, T.P., et al. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 173 (2013), 1549–1552.
3. 3 Ho, S.B., Nguyen, H., Tetrick, L.L., et al. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 96 (2001), 157–164.
4. 4 Rowan, P.J., Tabasi, S., Abdul-Latif, M., et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 38 (2004), 530–534.
5. 5 Rifai, M.A., Moles, J.K., Short, D.D., Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 57 (2006), 570–572.
6. 6 Gundlapalli, A.V., Nelson, R.E., Haroldsen, C., et al. Correlates of initiation of treatment for chronic hepatitis C infection in United States veterans, 2004–2009. PLoS One, 10, 2015, e0132056.
7. 7 Lam, B.P., Jeffers, T., Younoszai, Z., et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 8 (2015), 298–312.
8. 8 Morgan, T.R., Ghany, M.G., Kim, H.-Y., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (2010), 833–844.
9. 9 Morgan, R.L., Baack, B., Smith, B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
10. 10 Lawitz, E., Mangia, A., Wyles, D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
11. 11 Jacobson, I.M., Gordon, S.C., Kowdley, K.V., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368 (2013), 1867–1877.
12. 12 Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370 (2014), 1993–2001.
13. 13 Backus, L.I., Belperio, P.S., Shahoumian, T.A., et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 42 (2015), 559–573.
14. 14 Welzel, T.M., Nelson, D.R., Morelli, G., et al. Safety and efficacy of sofosbuvir and ribavirin for the treatment of HCV genotype 2 and 3: Results of the HCV-TARGET Study. Hepatology, 62(Suppl S1), 2015, 727A.
15. 15 Foster, G.R., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
16. 16 Department of Veterans Affairs. Chronic hepatitis C virus (HCV) infection: treatment considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health. Available at: http://www.hepatitis.va.gov/pdf/treatment-considerations-2015-02.pdf. Accessed November 9, 2015.
17. 17 Barua, S., Greenwald, R., Grebely, J., et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163 (2015), 215–223.
18. 18 Ho, S.B., Bräu, N., Cheung, R., et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol 13 (2015), 2005–2014.
19. 19 Feld, J.J., Jacobson, I.M., Hézode, C., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
20. 20 Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.